Uijttewaal Esther C H, Lee Joonsun, Sell Annika Charlotte, Botay Naomi, Vainorius Gintautas, Novatchkova Maria, Baar Juliane, Yang Jiaye, Potzler Tobias, van der Leij Sophie, Lowden Christopher, Sinner Julia, Elewaut Anais, Gavrilovic Milanka, Obenauf Anna, Schramek Daniel, Elling Ulrich
Institute of Molecular Biotechnology of the Austrian Academy of Science (IMBA), Dr. Bohr-Gasse 3, Vienna BioCenter (VBC), Vienna, Austria.
Vienna BioCenter PhD Program, University of Vienna and Medical University of Vienna, Vienna, Austria.
Nat Biotechnol. 2024 Dec 16. doi: 10.1038/s41587-024-02512-9.
Pooled genetic screening with CRISPR-Cas9 has enabled genome-wide, high-resolution mapping of genes to phenotypes, but assessing the effect of a given genetic perturbation requires evaluation of each single guide RNA (sgRNA) in hundreds of cells to counter stochastic genetic drift and obtain robust results. However, resolution is limited in complex, heterogeneous models, such as organoids or tumors transplanted into mice, because achieving sufficient representation requires impractical scaling. This is due to bottleneck effects and biological heterogeneity of cell populations. Here we introduce CRISPR-StAR, a screening method that uses internal controls generated by activating sgRNAs in only half the progeny of each cell subsequent to re-expansion of the cell clone. Our method overcomes both intrinsic and extrinsic heterogeneity as well as genetic drift in bottlenecks by generating clonal, single-cell-derived intrinsic controls. We use CRISPR-StAR to identify in-vivo-specific genetic dependencies in a genome-wide screen in mouse melanoma. Benchmarking against conventional screening demonstrates the improved data quality provided by this technology.
使用CRISPR-Cas9进行的汇集基因筛选能够实现全基因组范围内基因到表型的高分辨率映射,但评估给定基因扰动的效果需要在数百个细胞中评估每个单向导RNA(sgRNA),以对抗随机遗传漂变并获得可靠的结果。然而,在复杂的异质模型中,如类器官或移植到小鼠体内的肿瘤,分辨率受到限制,因为要实现足够的代表性需要不切实际的规模扩大。这是由于细胞群体的瓶颈效应和生物异质性。在这里,我们介绍了CRISPR-StAR,这是一种筛选方法,它在细胞克隆重新扩增后,仅在每个细胞的一半子代中激活sgRNA来产生内部对照。我们的方法通过产生克隆的、单细胞来源的内在对照,克服了内在和外在的异质性以及瓶颈中的遗传漂变。我们使用CRISPR-StAR在小鼠黑色素瘤的全基因组筛选中鉴定体内特异性基因依赖性。与传统筛选的基准测试表明,该技术提供了更高质量的数据。